Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral
Identifieur interne : 000391 ( Istex/Corpus ); précédent : 000390; suivant : 000392Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral
Auteurs : Girish J. Kotwal ; Jennifer N. Kaczmarek ; Steven Leivers ; Yohannes T. Ghebremariam ; Amod P. Kulkarni ; Gabriele Bauer ; Corena De Beer ; Wolfgang Preiser ; Abdu Rahman MohamedSource :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2005-11.
English descriptors
- Teeft :
- Acidic plant, Active ingredient, Antiviral, Antiviral activity, Antiviral drugs, Antiviral effects, Assay, Bioactive, Bioactive agent, Bioactive molecules, Cape town, Cell lines, Crude plant, Cutoff filter, Health sciences, Human immunodeficiency virus, Influenza virus, Kotwal, Life cycle, Liquid chromatography, Medical virology, Plaque formation, Significant effect, Toxicity, Trifollium species, Vaccinia, Vaccinia virus, Viral, Viral attachment, Viral infections, Viral infectivity, Viral loads, Virus, Virus noninfectious, Virus particles, West nile virus, York academy.
Abstract
Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (<10 ppm), and almost undetectable levels of arsenic (<1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.
Url:
DOI: 10.1196/annals.1352.014
Links to Exploration step
ISTEX:910558151BB0B6F28C15332032D15371ABD12055Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
<author><name sortKey="Kotwal, Girish J" sort="Kotwal, Girish J" uniqKey="Kotwal G" first="Girish J." last="Kotwal">Girish J. Kotwal</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: gjkotw01@yahoo.com</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaczmarek, Jennifer N" sort="Kaczmarek, Jennifer N" uniqKey="Kaczmarek J" first="Jennifer N." last="Kaczmarek">Jennifer N. Kaczmarek</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Leivers, Steven" sort="Leivers, Steven" uniqKey="Leivers S" first="Steven" last="Leivers">Steven Leivers</name>
<affiliation><mods:affiliation>Quantum House, Technopark, Stellenbosch, 6090, Uniedal, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ghebremariam, Yohannes T" sort="Ghebremariam, Yohannes T" uniqKey="Ghebremariam Y" first="Yohannes T." last="Ghebremariam">Yohannes T. Ghebremariam</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kulkarni, Amod P" sort="Kulkarni, Amod P" uniqKey="Kulkarni A" first="Amod P." last="Kulkarni">Amod P. Kulkarni</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bauer, Gabriele" sort="Bauer, Gabriele" uniqKey="Bauer G" first="Gabriele" last="Bauer">Gabriele Bauer</name>
<affiliation><mods:affiliation>Department of Medical Virology, NHLS, Tygerberg Business Unit, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="De Beer, Corena" sort="De Beer, Corena" uniqKey="De Beer C" first="Corena" last="De Beer">Corena De Beer</name>
<affiliation><mods:affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name>
<affiliation><mods:affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mohamed, Abdu Rahman" sort="Mohamed, Abdu Rahman" uniqKey="Mohamed A" first="Abdu Rahman" last="Mohamed">Abdu Rahman Mohamed</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:910558151BB0B6F28C15332032D15371ABD12055</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1196/annals.1352.014</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000391</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000391</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
<author><name sortKey="Kotwal, Girish J" sort="Kotwal, Girish J" uniqKey="Kotwal G" first="Girish J." last="Kotwal">Girish J. Kotwal</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: gjkotw01@yahoo.com</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaczmarek, Jennifer N" sort="Kaczmarek, Jennifer N" uniqKey="Kaczmarek J" first="Jennifer N." last="Kaczmarek">Jennifer N. Kaczmarek</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Leivers, Steven" sort="Leivers, Steven" uniqKey="Leivers S" first="Steven" last="Leivers">Steven Leivers</name>
<affiliation><mods:affiliation>Quantum House, Technopark, Stellenbosch, 6090, Uniedal, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ghebremariam, Yohannes T" sort="Ghebremariam, Yohannes T" uniqKey="Ghebremariam Y" first="Yohannes T." last="Ghebremariam">Yohannes T. Ghebremariam</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kulkarni, Amod P" sort="Kulkarni, Amod P" uniqKey="Kulkarni A" first="Amod P." last="Kulkarni">Amod P. Kulkarni</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bauer, Gabriele" sort="Bauer, Gabriele" uniqKey="Bauer G" first="Gabriele" last="Bauer">Gabriele Bauer</name>
<affiliation><mods:affiliation>Department of Medical Virology, NHLS, Tygerberg Business Unit, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="De Beer, Corena" sort="De Beer, Corena" uniqKey="De Beer C" first="Corena" last="De Beer">Corena De Beer</name>
<affiliation><mods:affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name>
<affiliation><mods:affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mohamed, Abdu Rahman" sort="Mohamed, Abdu Rahman" uniqKey="Mohamed A" first="Abdu Rahman" last="Mohamed">Abdu Rahman Mohamed</name>
<affiliation><mods:affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><biblScope unit="vol">1056</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="293">293</biblScope>
<biblScope unit="page" to="302">302</biblScope>
<biblScope unit="page-count">10</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-11">2005-11</date>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acidic plant</term>
<term>Active ingredient</term>
<term>Antiviral</term>
<term>Antiviral activity</term>
<term>Antiviral drugs</term>
<term>Antiviral effects</term>
<term>Assay</term>
<term>Bioactive</term>
<term>Bioactive agent</term>
<term>Bioactive molecules</term>
<term>Cape town</term>
<term>Cell lines</term>
<term>Crude plant</term>
<term>Cutoff filter</term>
<term>Health sciences</term>
<term>Human immunodeficiency virus</term>
<term>Influenza virus</term>
<term>Kotwal</term>
<term>Life cycle</term>
<term>Liquid chromatography</term>
<term>Medical virology</term>
<term>Plaque formation</term>
<term>Significant effect</term>
<term>Toxicity</term>
<term>Trifollium species</term>
<term>Vaccinia</term>
<term>Vaccinia virus</term>
<term>Viral</term>
<term>Viral attachment</term>
<term>Viral infections</term>
<term>Viral infectivity</term>
<term>Viral loads</term>
<term>Virus</term>
<term>Virus noninfectious</term>
<term>Virus particles</term>
<term>West nile virus</term>
<term>York academy</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (<10 ppm), and almost undetectable levels of arsenic (<1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>antiviral</json:string>
<json:string>viral</json:string>
<json:string>vaccinia</json:string>
<json:string>kotwal</json:string>
<json:string>cape town</json:string>
<json:string>toxicity</json:string>
<json:string>bioactive</json:string>
<json:string>york academy</json:string>
<json:string>antiviral activity</json:string>
<json:string>vaccinia virus</json:string>
<json:string>medical virology</json:string>
<json:string>virus particles</json:string>
<json:string>assay</json:string>
<json:string>life cycle</json:string>
<json:string>active ingredient</json:string>
<json:string>viral loads</json:string>
<json:string>west nile virus</json:string>
<json:string>bioactive agent</json:string>
<json:string>influenza virus</json:string>
<json:string>antiviral drugs</json:string>
<json:string>liquid chromatography</json:string>
<json:string>viral infections</json:string>
<json:string>antiviral effects</json:string>
<json:string>human immunodeficiency virus</json:string>
<json:string>health sciences</json:string>
<json:string>acidic plant</json:string>
<json:string>plaque formation</json:string>
<json:string>cutoff filter</json:string>
<json:string>crude plant</json:string>
<json:string>virus noninfectious</json:string>
<json:string>viral attachment</json:string>
<json:string>cell lines</json:string>
<json:string>bioactive molecules</json:string>
<json:string>trifollium species</json:string>
<json:string>viral infectivity</json:string>
<json:string>significant effect</json:string>
<json:string>virus</json:string>
</teeft>
</keywords>
<author><json:item><name>GIRISH J. KOTWAL</name>
<affiliations><json:string>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</json:string>
<json:string>E-mail: gjkotw01@yahoo.com</json:string>
</affiliations>
</json:item>
<json:item><name>JENNIFER N. KACZMAREK</name>
<affiliations><json:string>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</json:string>
</affiliations>
</json:item>
<json:item><name>STEVEN LEIVERS</name>
<affiliations><json:string>Quantum House, Technopark, Stellenbosch, 6090, Uniedal, South Africa</json:string>
</affiliations>
</json:item>
<json:item><name>YOHANNES T. GHEBREMARIAM</name>
<affiliations><json:string>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</json:string>
</affiliations>
</json:item>
<json:item><name>AMOD P. KULKARNI</name>
<affiliations><json:string>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</json:string>
</affiliations>
</json:item>
<json:item><name>GABRIELE BAUER</name>
<affiliations><json:string>Department of Medical Virology, NHLS, Tygerberg Business Unit, Cape Town, South Africa</json:string>
</affiliations>
</json:item>
<json:item><name>CORENA DE BEER</name>
<affiliations><json:string>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>WOLFGANG PREISER</name>
<affiliations><json:string>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>ABDU RAHMAN MOHAMED</name>
<affiliations><json:string>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>anti‐HIV</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>anti‐poxvirus</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Secomet‐V</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>anti‐SARS</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>broad‐spectrum antiviral</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>acidic plant extract</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>nontoxic</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>enveloped viruses</value>
</json:item>
</subject>
<articleId><json:string>NYAS293</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-9JZBVTVZ-L</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (>10 ppm), and almost undetectable levels of arsenic (>1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.</abstract>
<qualityIndicators><score>7.517</score>
<pdfWordCount>2709</pdfWordCount>
<pdfCharCount>16514</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>11</pdfPageCount>
<pdfPageSize>595 x 842 pts (A4)</pdfPageSize>
<pdfWordsPerPage>246</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>234</abstractWordCount>
<abstractCharCount>1579</abstractCharCount>
<keywordCount>8</keywordCount>
</qualityIndicators>
<title>Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
<pmid><json:string>16387696</json:string>
</pmid>
<genre><json:string>article</json:string>
</genre>
<host><title>Annals of the New York Academy of Sciences</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1749-6632</json:string>
</doi>
<issn><json:string>0077-8923</json:string>
</issn>
<eissn><json:string>1749-6632</json:string>
</eissn>
<publisherId><json:string>NYAS</json:string>
</publisherId>
<volume>1056</volume>
<issue>1</issue>
<pages><first>293</first>
<last>302</last>
<total>10</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>2005</json:string>
<json:string>2004</json:string>
</date>
<geogName></geogName>
<orgName><json:string>South Africa and Senior Entrance Fellowship and International Students</json:string>
<json:string>University of Cape Town, South Africa</json:string>
<json:string>University of Cape Town</json:string>
<json:string>RESULTS AND DISCUSSION Chemical Properties</json:string>
<json:string>Western Cape Police Department, Cape Town, South Africa</json:string>
<json:string>Virologic, Inc.</json:string>
<json:string>Poliomyelitis Research Foundation</json:string>
<json:string>South Africa ABSTRACT</json:string>
<json:string>Forensic Chemistry Laboratory, Cape Town Police Department</json:string>
<json:string>National Formulary, USA</json:string>
<json:string>Division of Medical Virology</json:string>
<json:string>PRF</json:string>
<json:string>Senior International</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>J. Kotwal</json:string>
<json:string>V. Assay</json:string>
<json:string>Independent</json:string>
<json:string>V. Secomet</json:string>
<json:string>Abubakar Jacobs</json:string>
<json:string>Andre Baard</json:string>
<json:string>N.Y. Acad</json:string>
</persName>
<placeName><json:string>Nile</json:string>
<json:string>Marburg</json:string>
<json:string>Germany</json:string>
<json:string>Cape Town</json:string>
<json:string>Toxicity</json:string>
<json:string>Congo</json:string>
<json:string>South Africa</json:string>
<json:string>San Francisco</json:string>
<json:string>Frankfurt</json:string>
<json:string>YORK</json:string>
<json:string>York</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>Ballardin et al.</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/WNG-9JZBVTVZ-L</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - multidisciplinary sciences</json:string>
</wos>
<scienceMetrix><json:string>1 - general</json:string>
<json:string>2 - general science & technology</json:string>
<json:string>3 - general science & technology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Social Sciences</json:string>
<json:string>2 - Arts and Humanities</json:string>
<json:string>3 - History and Philosophy of Science</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2005</publicationDate>
<copyrightDate>2005</copyrightDate>
<doi><json:string>10.1196/annals.1352.014</json:string>
</doi>
<id>910558151BB0B6F28C15332032D15371ABD12055</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-11"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
<author xml:id="author-0000" role="corresp"><persName><forename type="first">GIRISH J.</forename>
<surname>KOTWAL</surname>
</persName>
<affiliation><orgName type="department">Division of Medical Virology</orgName>
<orgName type="institution">Institute of Infectious Diseases and Molecular Medicine</orgName>
<orgName type="department">Faculty of Health Sciences</orgName>
<orgName type="institution">University of Cape Town</orgName>
<address><addrLine>Observatory</addrLine>
<addrLine>Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">JENNIFER N.</forename>
<surname>KACZMAREK</surname>
</persName>
<affiliation><orgName type="department">Division of Medical Virology</orgName>
<orgName type="institution">Institute of Infectious Diseases and Molecular Medicine</orgName>
<orgName type="department">Faculty of Health Sciences</orgName>
<orgName type="institution">University of Cape Town</orgName>
<address><addrLine>Observatory</addrLine>
<addrLine>Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">STEVEN</forename>
<surname>LEIVERS</surname>
</persName>
<affiliation><address><addrLine>Quantum House</addrLine>
<addrLine>Technopark, Stellenbosch, 6090, Uniedal, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">YOHANNES T.</forename>
<surname>GHEBREMARIAM</surname>
</persName>
<affiliation><orgName type="department">Division of Medical Virology</orgName>
<orgName type="institution">Institute of Infectious Diseases and Molecular Medicine</orgName>
<orgName type="department">Faculty of Health Sciences</orgName>
<orgName type="institution">University of Cape Town</orgName>
<address><addrLine>Observatory</addrLine>
<addrLine>Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">AMOD P.</forename>
<surname>KULKARNI</surname>
</persName>
<affiliation><orgName type="department">Division of Medical Virology</orgName>
<orgName type="institution">Institute of Infectious Diseases and Molecular Medicine</orgName>
<orgName type="department">Faculty of Health Sciences</orgName>
<orgName type="institution">University of Cape Town</orgName>
<address><addrLine>Observatory</addrLine>
<addrLine>Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">GABRIELE</forename>
<surname>BAUER</surname>
</persName>
<affiliation><orgName type="department">Department of Medical Virology</orgName>
<address><addrLine>NHLS</addrLine>
<addrLine>Tygerberg Business Unit, Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">CORENA</forename>
<surname>BEER</surname>
</persName>
<affiliation><orgName type="institution">Institute of Medical Virology</orgName>
<orgName type="institution">J.W. Goethe‐Universitat</orgName>
<address><addrLine>Frankfurt am Main</addrLine>
<addrLine>Germany</addrLine>
<country key="DE" xml:lang="en">GERMANY</country>
</address>
</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">WOLFGANG</forename>
<surname>PREISER</surname>
</persName>
<affiliation><orgName type="institution">Institute of Medical Virology</orgName>
<orgName type="institution">J.W. Goethe‐Universitat</orgName>
<address><addrLine>Frankfurt am Main</addrLine>
<addrLine>Germany</addrLine>
<country key="DE" xml:lang="en">GERMANY</country>
</address>
</affiliation>
</author>
<author xml:id="author-0008"><persName><forename type="first">ABDU RAHMAN</forename>
<surname>MOHAMED</surname>
</persName>
<affiliation><orgName type="department">Division of Medical Virology</orgName>
<orgName type="institution">Institute of Infectious Diseases and Molecular Medicine</orgName>
<orgName type="department">Faculty of Health Sciences</orgName>
<orgName type="institution">University of Cape Town</orgName>
<address><addrLine>Observatory</addrLine>
<addrLine>Cape Town, South Africa</addrLine>
<country key="ZA" xml:lang="en">SOUTH AFRICA</country>
</address>
</affiliation>
</author>
<idno type="istex">910558151BB0B6F28C15332032D15371ABD12055</idno>
<idno type="ark">ark:/67375/WNG-9JZBVTVZ-L</idno>
<idno type="DOI">10.1196/annals.1352.014</idno>
<idno type="unit">NYAS293</idno>
<idno type="toTypesetVersion">file:NYAS.NYAS293.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title>
<idno type="pISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<idno type="book-DOI">10.1111/(ISSN)1749-6632</idno>
<idno type="book-part-DOI">10.1111/nyas.2005.1056.issue-1</idno>
<idno type="product">NYAS</idno>
<idno type="publisherDivision">ST</idno>
<imprint><biblScope unit="vol">1056</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="293">293</biblScope>
<biblScope unit="page" to="302">302</biblScope>
<biblScope unit="page-count">10</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-11"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract xml:lang="en" style="main"><p>Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (<10 ppm), and almost undetectable levels of arsenic (<1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="k1">anti‐HIV</term>
<term xml:id="k2">anti‐poxvirus</term>
<term xml:id="k3">Secomet‐V</term>
<term xml:id="k4">anti‐SARS</term>
<term xml:id="k5">broad‐spectrum antiviral</term>
<term xml:id="k6">acidic plant extract</term>
<term xml:id="k7">nontoxic</term>
<term xml:id="k8">enveloped viruses</term>
</keywords>
<keywords rend="tocHeading1"><term>Article: Part V. Antiviral, Antimicrobial Live Vaccine and Plant Vaccines</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1749-6632</doi>
<issn type="print">0077-8923</issn>
<issn type="electronic">1749-6632</issn>
<idGroup><id type="product" value="NYAS"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup><title type="main" sort="ANNALS OF NEW YORK ACADEMY SCIENCES">Annals of the New York Academy of Sciences</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="11001"><doi origin="wiley">10.1111/nyas.2005.1056.issue-1</doi>
<titleGroup><title type="main">Natural Products and Molecular Therapy</title>
</titleGroup>
<numberingGroup><numbering type="journalVolume" number="1056">1056</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2005-11">November 2005</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="26" status="forIssue"><doi origin="wiley">10.1196/annals.1352.014</doi>
<idGroup><id type="unit" value="NYAS293"></id>
</idGroup>
<countGroup><count type="pageTotal" number="10"></count>
</countGroup>
<titleGroup><title type="tocHeading1">Article: Part V. Antiviral, Antimicrobial Live Vaccine and Plant Vaccines</title>
</titleGroup>
<eventGroup><event type="firstOnline" date="2006-01-22"></event>
<event type="publishedOnlineFinalForm" date="2006-01-22"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-19"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst" number="293">293</numbering>
<numbering type="pageLast" number="302">302</numbering>
</numberingGroup>
<correspondenceTo>Address for correspondence: Girish J. Kotwal, Division of Medical Virology, IIDMM, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa. Voice: +27‐21‐406‐6676; fax: +27‐21‐406‐6018; E‐mail: <email>gjkotw01@yahoo.com</email>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:NYAS.NYAS293.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="4"></count>
<count type="tableTotal" number="1"></count>
<count type="formulaTotal" number="0"></count>
<count type="referenceTotal" number="9"></count>
<count type="linksCrossRef" number="22"></count>
</countGroup>
<titleGroup><title type="main">Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the <i>Trifollium</i>
Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
</titleGroup>
<creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>GIRISH J.</givenNames>
<familyName>KOTWAL</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>JENNIFER N.</givenNames>
<familyName>KACZMAREK</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr3" affiliationRef="#a4"><personName><givenNames>STEVEN</givenNames>
<familyName>LEIVERS</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>YOHANNES T.</givenNames>
<familyName>GHEBREMARIAM</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>AMOD P.</givenNames>
<familyName>KULKARNI</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr6" affiliationRef="#a2"><personName><givenNames>GABRIELE</givenNames>
<familyName>BAUER</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr7" affiliationRef="#a3"><personName><givenNames>CORENA</givenNames>
<familyNamePrefix>DE</familyNamePrefix>
<familyName>BEER</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr8" affiliationRef="#a3"><personName><givenNames>WOLFGANG</givenNames>
<familyName>PREISER</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr9" affiliationRef="#a1"><personName><givenNames>ABDU RAHMAN</givenNames>
<familyName>MOHAMED</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="a1" countryCode="ZA"><unparsedAffiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</unparsedAffiliation>
</affiliation>
<affiliation xml:id="a2" countryCode="ZA"><unparsedAffiliation>Department of Medical Virology, NHLS, Tygerberg Business Unit, Cape Town, South Africa</unparsedAffiliation>
</affiliation>
<affiliation xml:id="a3" countryCode="DE"><unparsedAffiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="a4" countryCode="ZA"><unparsedAffiliation>Quantum House, Technopark, Stellenbosch, 6090, Uniedal, South Africa</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en"><keyword xml:id="k1">anti‐HIV</keyword>
<keyword xml:id="k2">anti‐poxvirus</keyword>
<keyword xml:id="k3">Secomet‐V</keyword>
<keyword xml:id="k4">anti‐SARS</keyword>
<keyword xml:id="k5">broad‐spectrum antiviral</keyword>
<keyword xml:id="k6">acidic plant extract</keyword>
<keyword xml:id="k7">nontoxic</keyword>
<keyword xml:id="k8">enveloped viruses</keyword>
</keywordGroup>
<abstractGroup><abstract type="main" xml:lang="en"><p>Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (<10 ppm), and almost undetectable levels of arsenic (<1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral</title>
</titleInfo>
<name type="personal"><namePart type="given">GIRISH J.</namePart>
<namePart type="family">KOTWAL</namePart>
<affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</affiliation>
<affiliation>E-mail: gjkotw01@yahoo.com</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JENNIFER N.</namePart>
<namePart type="family">KACZMAREK</namePart>
<affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">STEVEN</namePart>
<namePart type="family">LEIVERS</namePart>
<affiliation>Quantum House, Technopark, Stellenbosch, 6090, Uniedal, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">YOHANNES T.</namePart>
<namePart type="family">GHEBREMARIAM</namePart>
<affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">AMOD P.</namePart>
<namePart type="family">KULKARNI</namePart>
<affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">GABRIELE</namePart>
<namePart type="family">BAUER</namePart>
<affiliation>Department of Medical Virology, NHLS, Tygerberg Business Unit, Cape Town, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">CORENA</namePart>
<namePart type="family">DE BEER</namePart>
<affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">WOLFGANG</namePart>
<namePart type="family">PREISER</namePart>
<affiliation>Institute of Medical Virology, J.W. Goethe‐Universitat, Frankfurt am Main, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">ABDU RAHMAN</namePart>
<namePart type="family">MOHAMED</namePart>
<affiliation>Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo><publisher>Blackwell Publishing Ltd</publisher>
<place><placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2005-11</dateIssued>
<copyrightDate encoding="w3cdtf">2005</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><extent unit="figures">4</extent>
<extent unit="tables">1</extent>
<extent unit="formulas">0</extent>
<extent unit="references">9</extent>
<extent unit="linksCrossRef">22</extent>
</physicalDescription>
<abstract lang="en">Enveloped animal viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, human papillomavirus, Marburg, and influenza are major public health concerns around the world. The prohibitive cost of antiretroviral (ARV) drugs for most HIV‐infected patients in sub‐Saharan Africa and the serious side effects in those who have access to ARV drugs make a compelling case for the study of complementary and alternative therapies. Such therapies should have scientifically proved antiviral activity and minimal toxic effects. A plant extract, Secomet‐V, with an anecdotal indication in humans for promise as an anti‐HIV treatment, was investigated. Using a previously described attenuated vaccinia virus vGK5, we established the antiviral activity of Secomet‐V. Chemical analysis showed that it has an acidic pH, nontoxic traces of iron (<10 ppm), and almost undetectable levels of arsenic (<1.0 ppm). The color varies from colorless to pale yellow to dark brown. The active agent is heat stable at least up to sterilizing temperature of 121°C. The crude plant extract is a mixture of several small molecules separable by high‐pressure liquid chromatography. The HIV viral loads were significantly reduced over several months in a few patients monitored after treatment with Secomet‐V. Secomet‐V was also found to have antiviral activity against the SARS virus but not against the West Nile virus. Secomet‐V, therefore, is a broad‐spectrum antiviral, which possibly works by neutralizing viral infectivity, resulting in the prevention of viral attachment.</abstract>
<subject lang="en"><genre>keywords</genre>
<topic>anti‐HIV</topic>
<topic>anti‐poxvirus</topic>
<topic>Secomet‐V</topic>
<topic>anti‐SARS</topic>
<topic>broad‐spectrum antiviral</topic>
<topic>acidic plant extract</topic>
<topic>nontoxic</topic>
<topic>enveloped viruses</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Annals of the New York Academy of Sciences</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0077-8923</identifier>
<identifier type="eISSN">1749-6632</identifier>
<identifier type="DOI">10.1111/(ISSN)1749-6632</identifier>
<identifier type="PublisherID">NYAS</identifier>
<part><date>2005</date>
<detail type="title"><title>Natural Products and Molecular Therapy</title>
</detail>
<detail type="volume"><caption>vol.</caption>
<number>1056</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>293</start>
<end>302</end>
<total>10</total>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="cit1"><titleInfo><title>HIV treatment and eradication in South Africa</title>
</titleInfo>
<name type="personal"><namePart type="given">G.J.</namePart>
<namePart type="family">Kotwal</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Kotwal, G.J. 2004. HIV treatment and eradication in South Africa. J. R. Soc. Med. 97: 1–2.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>97</number>
</detail>
<extent unit="pages"><start>1</start>
<end>2</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J. R. Soc. Med.</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>97</number>
</detail>
<extent unit="pages"><start>1</start>
<end>2</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit2"><titleInfo><title>Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections</title>
</titleInfo>
<name type="personal"><namePart type="given">E.</namePart>
<namePart type="family">De Clercq</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2: 382–397.</note>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>382</start>
<end>397</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Clin. Microbiol. Rev.</title>
</titleInfo>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>382</start>
<end>397</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit3"><titleInfo><title>Korean medicinal plant extracts exhibit antiviral potency against viral hepatitis</title>
</titleInfo>
<name type="personal"><namePart type="given">J.R.</namePart>
<namePart type="family">Jacob</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Jacob, J.R. et al. 2004. Korean medicinal plant extracts exhibit antiviral potency against viral hepatitis. J. Alt. Compl. Med. 10: 1019–1026.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<extent unit="pages"><start>1019</start>
<end>1026</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J. Alt. Compl. Med.</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<extent unit="pages"><start>1019</start>
<end>1026</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit4"><titleInfo><title>Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo</title>
</titleInfo>
<name type="personal"><namePart type="given">F.</namePart>
<namePart type="family">Notka</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Notka, F. et al. 2004. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res. 64: 93–102.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>64</number>
</detail>
<extent unit="pages"><start>93</start>
<end>102</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Antiviral Res.</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>64</number>
</detail>
<extent unit="pages"><start>93</start>
<end>102</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit5"><titleInfo><title>Punica granatum (Pomegranate) juice provides an HIV‐entry inhibitor and candidate topical microbicide</title>
</titleInfo>
<name type="personal"><namePart type="given">A.R.</namePart>
<namePart type="family">Neurath</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Neurath, A.R. et al. 2004. Punica granatum (Pomegranate) juice provides an HIV‐entry inhibitor and candidate topical microbicide. BMC Infect. Dis. 4: 41–52.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>4</number>
</detail>
<extent unit="pages"><start>41</start>
<end>52</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>BMC Infect. Dis.</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>4</number>
</detail>
<extent unit="pages"><start>41</start>
<end>52</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit6"><titleInfo><title>Growing poxviruses and determining virus titer</title>
</titleInfo>
<name type="personal"><namePart type="given">G.J.</namePart>
<namePart type="family">Kotwal</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>other</genre>
<part><date>2004</date>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="cit7"><titleInfo><title>A novel approach using an attenuated recombinant vaccinia virus to test the antiviral effects of handsoaps</title>
</titleInfo>
<name type="personal"><namePart type="given">E.A.</namePart>
<namePart type="family">Jonczy</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Jonczy, E.A., J. Daly & G.J. Kotwal. 2000. A novel approach using an attenuated recombinant vaccinia virus to test the antiviral effects of handsoaps. Antiviral Res. 45: 149–153.</note>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>45</number>
</detail>
<extent unit="pages"><start>149</start>
<end>153</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Antiviral Res.</title>
</titleInfo>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>45</number>
</detail>
<extent unit="pages"><start>149</start>
<end>153</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit8"><titleInfo><title>Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800 Da secretory protein</title>
</titleInfo>
<name type="personal"><namePart type="given">G.J.</namePart>
<namePart type="family">Kotwal</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Kotwal, G.J., A.W. Huegin & B. Moss. 1989. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800 Da secretory protein. Virology 171: 579–587.</note>
<part><date>1989</date>
<detail type="volume"><caption>vol.</caption>
<number>171</number>
</detail>
<extent unit="pages"><start>579</start>
<end>587</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Virology</title>
</titleInfo>
<part><date>1989</date>
<detail type="volume"><caption>vol.</caption>
<number>171</number>
</detail>
<extent unit="pages"><start>579</start>
<end>587</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="cit9"><titleInfo><title>Lack of N1L gene expression results in significant decrease in vaccinia virus replication in mice brain</title>
</titleInfo>
<name type="personal"><namePart type="given">B.</namePart>
<namePart type="family">Billings</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Billings, B., S.A. Smith, Z. Zhang, et al. 2004. Lack of N1L gene expression results in significant decrease in vaccinia virus replication in mice brain. Ann. N.Y. Acad. Sci. 1030: 297–302.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>1030</number>
</detail>
<extent unit="pages"><start>297</start>
<end>302</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Ann. N.Y. Acad. Sci.</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>1030</number>
</detail>
<extent unit="pages"><start>297</start>
<end>302</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<identifier type="istex">910558151BB0B6F28C15332032D15371ABD12055</identifier>
<identifier type="ark">ark:/67375/WNG-9JZBVTVZ-L</identifier>
<identifier type="DOI">10.1196/annals.1352.014</identifier>
<identifier type="ArticleID">NYAS293</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-9JZBVTVZ-L/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000391 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000391 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:910558151BB0B6F28C15332032D15371ABD12055 |texte= Anti‐HIV, Anti‐Poxvirus, and Anti‐SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet‐V/anti‐Vac Suggests That It Contains a Novel Broad‐Spectrum Antiviral }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |